91results about How to "Reduce neurotoxicity" patented technology

This invention provides methods and compositions for the detection, diagnosis and treatment of amyloid-associated diseases, in particular, diseases comprising deposition of amyloid assemblies, fibrils, filaments, tangles, or plaques. A preferred composition comprises monoclonal antibodies that specifically bind amyloid proteins, peptides or fragments and change the conformation.

The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Abeta protein, including abeta_1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a major or minor depressive episode/disorder attributed to elevated levels of Abeta protein, including abeta_1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders by administering an agent that either prevents production of Abeta, prevents aggregation of Abeta fibrils, or that increases the degradation or clearance of Abeta. In addition, the invention provides a method of treating or preventing a major or minor depressive disorder comprising administering an agent that prevents or interferes with Abeta-induced neurotoxicity. The present invention also relates to pharmaceutical compositions comprising such agents and methods of screening for novel agents.

The invention relates to methods for identifying candidate pharmacological agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathological conditions.

This invention relates to compounds of general formula (I), wherein R₁, R₂, R₃, R₄ and R₅ are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumour activity and lower nervous system toxicity by structurally modification of the parent structure of β-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumour medicines and medicines used in treatment of tumour diseases in combination of light or radiation therapy.

The invention relates to a preparation method of acetyl levocarnitine hydrochloride, and drug application of the acetyl levocarnitine hydrochloride. The preparation method comprises the following steps of: (1) mixing acetic acid and levocarnitine base, and then stirring to prepare an acetic acid solution of the levocarnitine base, wherein the mass ratio of the acetic acid to the levocarnitine base is 1: 0.6 to 1.2; (2) mixing hydrochloric acid and acetyl chloride, and then stirring to prepare an acylation reagent, wherein the mass ratio of the hydrochloric acid to the acetyl chloride is 1: 2 to 4; and (3) mixing the acetic acid solution of the levocarnitine base and the acylation reagent, and performing acylation reaction to prepare the acetyl levocarnitine hydrochloride. The method is easy to operate and low in cost. Waste gas can be avoided. Drugs with the acetyl levocarnitine hydrochloride as an active ingredient are used for treating mechanical and inflammatory damages of peripheral nerve trunks or nerve roots with good effect.

The invention relates to a method for purifying slime water by compounding biological and abiological flocculants of coal. The method comprises the following steps: by taking polyacrylamide (PAM) and phanerochaete chrysosporium which are in the volume ratio of 1:X as compounding flocculants, adding 1ml to 4ml of CaCl2, which accounts for 2% of the mass percent of the compounding flocculants under a certain slime water concentration; regulating the PH (Potential Of Hydrogen) of the slime water to reach 4 to 8 and other external conditions; and carrying out flocculation sedimentation on the slime water under a series of biological and abiological actions. According to the method, the adding quantity of the abiological flocculants of the coal is reduced while the flocculation effect of the slime water in a coal preparation plant is not influenced, so that the limits of various factors to the flocculation effect are decreased; the application range of the compounding flocculants is enlarged; and the pollution and the toxic action of inorganic salts and organic flocculants to environments are relieved.

The invention discloses a compound traditional Chinese medicinal extract, which comprises (by weight ratio) epimeddium 1167, dipsacus root 167, root of red rooted saliva 83, anemarrhena rhizome 83, psoralea fruit 83, dried rehmannia root 83, and right amount of pharmaceutically acceptable adjuvant or base material. The compound can be prepared into the dosage form of soft capsule, emulsifying tablet and dressed dispersing tablet, which can be used for treating women's climacteric osteoporosis and senile dementia.

The invention features methods for treating neurotoxicity associated with therapeutic agents, e.g., chemotherapeutic agents, and compositions and kits for use therein. The methods employ an extract of Ginkgo biloba to mitigate the neurotoxic effects of the therapeutic agents.

The present invention relates to the method of treating chemotherapy-induced neuropathy in a subject in need thereof with the use of a poly(ADP-ribose)polymerase (PARP) inhibitor.

The invention relates to a cathearanthus alkaloid, belonging to medical alkaloid and derivative thereof. The cathearanthus alkaloid is obtained by structural modification of 6'-N oxidation-epoxy catharanthine, and solves the problems of low antitumor activity and high toxic side effect on nerves of the existing cathearanthus alkaloid. The cathearanthus alkaloid is obtained by semi-synthetic modification of the third site of the 6'-N oxidation- epoxy catharanthine; besides, the fourth site of the 6'-N oxidation- epoxy catharanthine can be further semi-synthetically modified for preparing antitumor medicines. Proven by a median lethal dose (IC50) experiment of cancer cell lines and an animal experiment of mice, the compounds of the invention have favorable antitumor activity and low nerve toxicity, and is of great significance to the development of new antitumor medicines.

The invention provides a Chinese medicinal composition for treating cerebral apoplexy, wherein the active constituents of the composition comprises (by weight ratio): acorus gramineus soland 50-500, rhizome of Sichuan lovage 50-500, borneol 1-10.

Disclosed are a composition for reducing beta amyloid-induced neurotoxicity by inhibiting β-secretase activity, comprising a dibenzofuran derivative, and a method for preparing the same. Further disclosed is that the combination of the dibenzofuran derivative with a γ-secretase inhibitor or an anti-inflammatory agent shows higher activity with respect to reducing beta amyloid-induced neurotoxicity.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

A lipid composition of vincristine sulfate in the form freeze dried powder for intravenous injection or drip is prepared from the vincristine sulfate, phosphatide and cholesterin.

The invention discloses a class of carbamate-chalcone cholinesterase inhibitors and a preparation method and application thereof, belonging to the field of medicinal chemistry. The general chemical structure formula of the cholinesterase inhibitor of the present invention is shown in formula (I), wherein A, B, V, X, Y, and Z are as defined in the present invention. The carbamate-chalcone cholinesterase inhibitor of the present invention has stronger acetylcholinesterase inhibitor activity, butyrylcholinesterase inhibitory activity and selective inhibition of butyrylcholinesterase activity, It has lower neurotoxicity and can be applied to the preparation of medicines for treating and preventing diseases caused by cholinesterase.